Nuclear/Biological/Chemical (NBC) Defense - Federation of ...

More documents

Recommendations

Info

• Awarded a manufacturing development contract. • NDA is under preparation. Product: Multichambered Autoinjector Joint Medical NBC Defense Research Programs Concept: • Speed administration of life-saving antidotes against nerve agents. • Replace two-Injector Mark I Nerve Agent Antidote Kit with single autoinjector. Status: • Engineering contract awarded in September 1993. • Fielding will require full FDA approval. • Demonstrated the human safety of the multi-chambered autoinjector. • Engineering and development of final prototype completed. Product: Cyanide Pretreatment Concept: • Provide protection against incapacitation and lethality without performance degradation. • Enhance soldier protection and sustainment. Status: • Completed preclinical toxicology and drug distribution studies. • Developed dose parameters and performance assessments. • Concluded animal toxicology studies for cyanide pretreatment. • Completed preparation of IND application. • Initial efforts to conduct first human safety tests. • Draft Engineering and Manufacturing Development Request for Proposals undergoing staffing. D-9
NBC Defense Annual Report D-10 D.2 MEDICAL BIOLOGICAL DEFENSE RESEARCH PROGRAM D.2.1 Biological Defense Products Advances in DoD medical R&D significantly impact the warfighting mission by sustaining unit effectiveness through conserving the fighting strength of our soldiers and supporting the nation’s global military strategy, which requires the ability to effectively deploy and operate. Medical R&D products (materiel and non-materiel solutions) provide the foundation that ensures the fielding of a flexible, sustainable, modernized force across the spectrum of conflict and in the full breadth and depth of the battlefield. Overcoming medical threats and extending human performance have provided a significant increase in military effectiveness in the past and present the potential for future enhancement of military operational effectiveness. Some of the materiel and non-materiel solutions developed for use in medical biological defense R&D include the following: Vaccines and Antisera: • Anthrax Vaccine (licensed) • Plague Vaccine (licensed)* • Smallpox Vaccine (licensed) • Botulinum Toxoid Vaccine, Pentavalent (IND #3723) • Botulinum Type F Toxoid Vaccine (IND #5077) • Botulinum Antitoxin, Heptavalent Equine (Types A, B, C, D, E, F, and G) (IND #3703) • Botulism Immune Globulin, Human (IND #1332) • Botulism, Antitoxin, Heptavalent Equine, Types A, B, C, D, E, F, and G (IND #5077) • Q Fever Vaccine, Purified Whole Cell, CM Residue, Formalin Inactivated, Gamma Irradiated (IND #3516) • Tularemia Vaccine (IND #157) • Vaccinia Virus Vaccine, Cell Cultured (IND #4984) • Venezuelan Equine Encephalitis Virus Vaccine, TC-83 (IND #142) • Eastern Equine Encephalitis Virus Vaccine (IND #266) • Western Equine Encephalitis Virus Vaccine (IND #2013) *Plague vaccine is licensed against bubonic plague but is probably not effective against aerosolized Yersinia pestis (Plague) Technical Information and Guidance: • Handbook “Medical Management of Biological Casualties,” 1998. • In FY98, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), in collaboration with the Centers for Disease Control and Prevention, broadcast a live, interactive satellite distance learning course entitled “Medical Response to Biological Warfare and Terrorism” to 17,319 military and civilian health professionals and first responders at 500 sites across the United States. This 3-day course proved to be very cost-effective, as the cost was $69 per student trained; whereas, it costs an estimated $1,000 to train a health care provider at USAMRIID’s resident in-house course, which is
Page 1 and 2:
DEPARTMENT OF DEFENSE NUCLEAR/BIOLO
Page 3 and 4:
Executive Summary The National Defe
Page 5 and 6:
OVERVIEW OF REPORT Executive Summar
Page 7 and 8:
Table of Contents Page EXECUTIVE SU
Page 9 and 10:
Table of Contents 5. Medical.......
Page 11 and 12:
Table of Contents TABLES AND FIGURE
Page 13 and 14:
I. PURPOSE Introduction This report
Page 15 and 16:
II. THE CURRENT CHEMICAL AND BIOLOG
Page 17 and 18:
Introduction However, it is suspect
Page 19 and 20:
purchase dual-use biotech equipment
Page 21 and 22:
Chapter 1 DoD Chemical and Biologic
Page 23 and 24:
Program Management and Oversight Th
Page 25 and 26:
Program Management and Oversight it
Page 27 and 28:
Program Management and Oversight ac
Page 29 and 30:
Chapter 2 Non-Medical Nuclear, Biol
Page 31 and 32:
Non-Medical NBC Defense Requirement
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
2.4 PROTECTION Non-Medical NBC Defe
Page 41 and 42:
Page 43 and 44:
Table 2-7. Protection RDA Efforts N
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
2.5.3 Joint Service Decontamination
Page 53 and 54:
Page 55 and 56:
Chapter 3 Medical Nuclear, Biologic
Page 57 and 58:
Medical NBC Defense Requirements an
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Chapter 4 Nuclear, Biological, and
Page 75 and 76:
NBC Defense Logistics Status requir
Page 77 and 78:
NBC Defense Logistics Status Both D
Page 79 and 80:
RISK ASSESSMENT: NBC Defense Logist
Page 81 and 82:
Table 4-1. Logistic Risk Assessment
Page 83 and 84:
NBC Defense Logistics Status protec
Page 85 and 86:
4.8 NBC DEFENSE LOGISTICS SUPPORT A
Page 87 and 88:
4-15 NOMENCLATURE NSN TOTAL SERVICE
Page 89 and 90:
4-17 Table 4-2b. Army Logistics Rea
Page 91 and 92:
4-19 Table 4-3b. Air Force Logistic
Page 93 and 94:
4-21 NOMENCLATURE NSN TOTAL SERVICE
Page 95 and 96:
4-23 Table 4-4b. Navy Logistics Rea
Page 97 and 98:
4-25 Table 4-5b. Marine Corps Logis
Page 99 and 100:
4-27 Table 4-6. Defense Logistics A
Page 101 and 102:
APPENDIX 2 FIELDED NBC DEFENSE ITEM
Page 103 and 104:
NBC Defense Logistics Status manufa
Page 105 and 106:
NBC Defense Logistics Status requir
Page 107 and 108:
NBC Defense Logistics Status The M2
Page 109 and 110:
5.1 INTRODUCTION Chapter 5 Nuclear,
Page 111 and 112:
NBC Defense Readiness and Training
Page 113 and 114:
Page 115 and 116:
In FY 98, 38 courses were taught co
Page 117 and 118:
Page 119 and 120:
5.3.3 Navy NBC Defense Readiness an
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
5.4.5 Marine Corps NBC Defense Prof
Page 129 and 130:
5.6 INTEGRATION OF REALISM/WARGAMES
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
5.7.3 Air Force NBC Defense Readine
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
NBC Defense Annual Report CW muniti
Page 147 and 148:
NBC Defense Annual Report 6-4 (INTE
Page 149 and 150:
NBC Defense Annual Report fielded t
Page 151 and 152:
NBC Defense Annual Report A-4 M272
Page 153 and 154:
NBC Defense Annual Report the M8A1
Page 155 and 156: NBC Defense Annual Report platform
Page 157 and 158: NBC Defense Annual Report A-10 SECT
Page 159 and 160: NBC Defense Annual Report A-12 Ship
Page 161 and 162: NBC Defense Annual Report A-14 to a
Page 163 and 164: NBC Defense Annual Report A-16 Crit
Page 165 and 166: NBC Defense Annual Report A-18 will
Page 167 and 168: NBC Defense Annual Report A-20 NBC
Page 169 and 170: NBC Defense Annual Report A-22 (INT
Page 171 and 172: NBC Defense Annual Report B-2 MCU-2
Page 173 and 174: NBC Defense Annual Report B-4 ANCIL
Page 175 and 176: NBC Defense Annual Report B-6 Chemi
Page 177 and 178: NBC Defense Annual Report B-8 Chemi
Page 179 and 180: NBC Defense Annual Report Chemicall
Page 181 and 182: NBC Defense Annual Report B-12 Port
Page 183 and 184: NBC Defense Annual Report B-14 SECT
Page 185 and 186: NBC Defense Annual Report B-16 Ligh
Page 187 and 188: NBC Defense Annual Report Descripti
Page 189 and 190: NBC Defense Annual Report B-20 •
Page 191 and 192: NBC Defense Annual Report B-22 (INT
Page 193 and 194: NBC Defense Annual Report C-2 M295
Page 195 and 196: NBC Defense Annual Report C-4 SECTI
Page 197 and 198: NBC Defense Annual Report C-6 M17 D
Page 199 and 200: NBC Defense Annual Report Materiel:
Page 201 and 202: NBC Defense Annual Report D-4 • E
Page 203 and 204: NBC Defense Annual Report D-6 • S
Page 205: NBC Defense Annual Report D-8 • S
Page 209 and 210: NBC Defense Annual Report D-12 •
Page 213 and 214: NBC Defense Annual Report D-16 ferm
Page 215 and 216: NBC Defense Annual Report D-18 viru
Page 223 and 224: NBC Defense Annual Report tissue in
Page 227 and 228: NBC Defense Annual Report D-30 Thre
Page 229 and 230: Annex E Joint Nuclear, Biological,
Page 231 and 232: E-3 ($ in millions) 900 800 700 600
Page 233 and 234: Annex F Nuclear, Biological, and Ch
Page 235 and 236: NBC Defense Internet Sites United S
Page 237 and 238: Annex G Statement Regarding Chemica
Page 239 and 240: Annex H Congressional Reporting Req
Page 241 and 242: -A- AAAV - Advanced Amphibious Assa
Page 243 and 244: DSO - Defense Sciences Office DTAP
Page 245 and 246: metL, thrA - methionine biosynthesi
Page 247: -V- VCA - Voice Communication Adapt
show all

Nuclear/Biological/Chemical (NBC) Defense - Federation of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?